Funding for this research was provided by:
Canadian Institute for Advanced Research
ALS Society of Canada
Fondation Brain Canada
Received: 15 May 2020
Accepted: 14 December 2020
First Online: 7 January 2021
: JPJ holds shares in IMSTAR Therapeutics which provided the IMS-088 compound. All other authors have no competing interests.